

Cannabidiol modulates the motivational and anxiety-like effects of 3,4-methylenedioxypyrovalerone (MDPV) in mice

Laia Alegre-Zurano¹, Raúl López-Arnau^{3*}, Miguel Á. Luján^{1,a}, Jordi Camarasa³, Olga Valverde^{1,2*}

1. Neurobiology of Behaviour Research Group (GReNeC-NeuroBio), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain

2. Neuroscience Research Programme, IMIM-Hospital del Mar Research Institute, Barcelona, Spain.

3. Department of Pharmacology, Toxicology and Therapeutic Chemistry, Pharmacology Section and Institute of Biomedicine (IBUB) Faculty of Pharmacy and Food Sciences, Universitat de Barcelona, Barcelona, Spain.

Present address:

^a Department of Anatomy and Neurobiology, University of Maryland School of Medicine, Baltimore, MD, USA.

*Author for correspondence:

Olga Valverde
Neurobiology of Behaviour Research Group (GReNeC - NeuroBio),
Department of Experimental and Health Sciences,
Universitat Pompeu Fabra
Dr. Aiguader 88; Barcelona 08003
olga.valverde@upf.edu

Raúl López-Arnau
Department of Pharmacology, Toxicology and Therapeutic Chemistry, Pharmacology Section and Institute of Biomedicine (IBUB) Faculty of Pharmacy and Food Sciences, Universitat de Barcelona, Barcelona, Spain.
raullopezarnau@ub.edu

ABSTRACT

3,4-methylenedioxypyrovalerone (MDPV) is a new psychoactive substance (NPS) and the most widespread and life-threatening synthetic cathinone of the “bath salts”. Preclinical research has proven the cocaine-like psychostimulant effects of MDPV and its potential for abuse. Cannabidiol (CBD) is a non-psychotropic phytocannabinoid that has emerged as a new potential treatment for drug addiction. Here, we tested the effects of CBD (20 mg/kg) on MDPV (2 mg/kg)-induced conditioned place preference and MDPV (0.05 and 0.075 mg/kg/infusion) self-administration paradigm. We also assessed the effects of the combination of CBD, and MDPV (3 and 4 mg/kg) on anxiety-like behaviour using the elevated plus maze (EPM). CBD mitigated the MDPV-induced conditioned place preference. On the contrary, CBD administration throughout the MDPV (0.075 mg/kg/infusion) self-administration increased drug-seeking and taking behaviours, but only in the high-responders group of mice. Additionally, CBD exerted anxiolytic-like effects, but only in MDPV-treated mice. Taken together, our results indicate that CBD modulation of MDPV-induced motivational responses in mice vary depending on the requirements of the learning task, resulting in a complex response. More research attempting to decipher the behavioural and molecular interactions between CBD and MDPV is needed.

Keywords: MDPV, cannabidiol, conditioned place preference, self-administration, anxiety, mice

HIGHLIGHTS

- MDPV induces conditioned place preference and self-administration in mice
- CBD slightly mitigates MDPV-induced conditioned place preference
- CBD increases MDPV (0.075 mg/kg/infusion) self-administration only in the high-responders mice
- CBD exerts anxiolytic-like effects when administered in combination with MDPV

ABBREVIATIONS

CBD: cannabidiol

CPP: conditioned place preference

DAT: dopamine transporter

EPM: elevated plus maze

FR1: fixed ratio 1

MDMA: 3,4-methylenedioxymethamphetamine

MDPV: 3,4-methylenedioxypyrovalerone

NET: norepinephrine transporter

NPS: new psychoactive substances

PR: progressive ratio

SERT: serotonin transporter

1. INTRODUCTION

Hundreds of new psychoactive substances (NPS) have been synthesized in the last years (United Nations publication, 2020). In Europe, synthetic cathinones and cannabinoids account for 77% of all seizures of NPS (EMCDDA, 2020). The elevated use of synthetic cathinones as “legal highs” has raised concern due to their risk for abuse and dependence. Among them, 3,4-methylenedioxypyrovalerone (MDPV) is one of the most widespread and life-threatening components of the so-called “bath salts” (Baumann et al., 2017; Karch, 2014). Together with euphoria and enhanced energy, the use of MDPV is related to hyperthermia, dehydration, sweating, loss of appetite, disturbed sleep patterns and consciousness alterations (Karila et al., 2018). High doses of MDPV can cause severe symptoms, including hallucinations, psychosis, seizures or even death (Ross et al., 2012).

MDPV is a potent uptake inhibitor of the dopamine transporter (DAT) and norepinephrine transporter (NET), with weaker activity at serotonin transporter (SERT) (Baumann et al., 2017; Simmler et al., 2012). Compared to cocaine, MDPV is 50-fold more potent as an inhibitor at DAT (Baumann et al., 2017). Notably, MDPV administered intravenously (i.v.) increases nucleus accumbens dopamine and locomotor activity in rats at one-tenth the dose of cocaine (Baumann et al., 2013). Consistent with this mechanism of action, some authors found that MDPV has powerful rewarding effects measured by ultrasonic vocalizations in rats in the self-administration paradigm (Simmons et al., 2018, 2017). In the same line, MDPV-induced rewarding effects in the conditioned place preference (CPP) in mice (Duart-Castells et al., 2020) and rats (Hicks et al., 2018; Risca et al., 2020).

Previous studies reported that MDPV works as a reinforcer for intravenous self-administration in rats (Aarde et al., 2015b, 2015a, 2013; Gannon et al., 2017a; Geste et al., 2018; Schindler et al., 2016; Sewalia et al., 2018; Watterson et al., 2014). However, although Fantegrossi et al. (2013) demonstrated that mice discriminate between MDPV (0.3 mg/kg i.p.) and saline in an operant paradigm, MDPV self-administration studies using mice are very scarce. In fact, only one study to date reported MDPV (0.3 mg/ml p.o.) self-administration in a two-bottle choice paradigm, showing an escalated oral consumption along days (Gannon et al., 2017b). However, no study to date has tested MDPV operant self-administration in mice.

Lately, the phytocannabinoid cannabidiol (CBD) has emerged as a potential treatment for neuropsychiatry disorders (Elsaid et al., 2019), including anxiety (de Mello Schier et al., 2014), depression (García-Gutiérrez et al., 2020), and drug abuse (Chye et al., 2019). CBD effects are complex due to its wide variety of targets within the central nervous system (Izzo et al., 2009), including the agonism at 5-hydroxytryptamine 1A, transient potential vanilloid 1, G-protein 55 and peroxisome proliferator-activated gamma receptors, the blockade of adenosine reuptake (Izzo et al., 2009) and the negative allosteric modulation of cannabinoid receptors type 1 and 2 (Laprairie et al., 2015; Martínez-Pinilla et al., 2017). Regarding addiction, previous literature has pointed out the protective role of CBD for the treatment of psychostimulants abuse (Calpe-López et al., 2019; Rodrigues et al., 2020). Our team reported that CBD (20 mg/kg) decreased cocaine-induced acquisition of CPP in mice (Luján et al., 2018) and cocaine-maintained self-administration (Alegre-Zurano et al., 2020a; Luján et al., 2019, 2018), as well as cocaine-induced drug-seeking behaviour (Luján et al., 2018). Similarly, Parker et al. (2004) found that CBD potentiated the extinction of both cocaine-induced and amphetamine-induced CPP in rats and methamphetamine-induced drug-seeking behaviour (Hay et al., 2018).

Therefore, in the present study, we evaluated the effects of CBD on the rewarding and reinforcing effects induced by MDPV. We first investigated the effects of MDPV on the acquisition of CPP. Then, we also examined the reinforcing effects of MDPV at two different doses in the intravenous self-administration and progressive ratio test in mice and the effects of CBD in such a paradigm. We also assessed the effects of the combination of CBD and MDPV on anxiety-like behaviour using the elevated plus maze (EPM) in mice.

2. METHODS

2.1. Animals

Eight-week-old male CD1 mice were purchased (Charles River, Barcelona, Spain) and transported to our animal facility (UBIOMEX, PRBB). Each mouse only underwent one behavioural test (CPP, n=39; Self-administration, n=72; EPM, n=36). Mice that underwent CPP or EPM were maintained in a light-dark cycle, with lights turned off between 19:30 and 07:30. Mice that underwent self-administration were maintained in a reverse light-dark cycle, with lights turned off between 07:30 and 19:30. The

UPF/PRBB Animal Ethics Committee (CEEAA-PRBB-UPF) approved all animal care and experimental protocols, in accordance with European Community Council guidelines (2016/63/EU).

2.2. Drugs

MDPV hydrochloride was synthesized in our laboratory (IBUB, Universitat de Barcelona), and dissolved in 0.9% NaCl. CBD (20 mg·kg⁻¹ i.p.) was kindly provided by Phytoplant Research S.L., (Córdoba, Spain) and was suspended in a 0.9% NaCl solution containing 2% Tween-80.

2.3. Conditioned place preference

The test was carried out as previously described (Alegre-Zurano et al., 2020b; Luján et al., 2018). The apparatus consisted of two conditioning compartments that differed in visual and tactile cues (30×29×35 cm) connected by a grey-coloured tunnel (14×29×35 cm) (Cibertec S.A., Madrid, Spain). Briefly, during the pretest, mice were placed in the central compartment and left free to move in the three compartments for 20 minutes. During the conditioning phase (4 MDPV pairings, 8 days), mice received an injection of MDPV (2 mg/kg, i.p.) immediately before being placed into one of the two conditioning compartments for 30 min. On alternate days, mice were treated with a saline injection and placed in the other compartment for 30 min. Control animals received saline every day. CBD (20 mg/kg, i.p.) or vehicle was administered during the 8 conditioning days 30 minutes before the MDPV/saline injection. Twenty-four hours after the conditioning phase, mice were tested in the same conditions as in the pretest. Time spent in the compartment associated with MDPV was measured in the pretest and test as a measure of the degree of conditioning induced by the drug.

2.4. Self-administration

2.4.1. Surgery

The surgical procedure was conducted as previously described (Alegre-Zurano et al., 2020a; Soria et al., 2005). Surgical implantation of the catheter into the jugular vein was performed following anaesthetization with a mixture of ketamine hydrochloride (75 mg·kg⁻¹; Imalgène1000, Lyon, France) and medetomidine hydrochloride (1 mg·kg⁻¹; Medeson®, Barcelona, Spain). Briefly, a 6 cm length of silastic tubing (0.3 mm inner diameter, 0.6 mm outer diameter) (silastic, Dow Corning, Houdeng-Goegnies, Belgium)

was fitted to a 22-gauge steel cannula (Semat, Herts, England). The catheter tubing was inserted 1.3 cm into the right jugular vein and anchored with a suture. The remaining tubing ran subcutaneously to the cannula, which exited at the mid-scapular region.

Meloxicam ($0.5 \text{ mg} \cdot \text{kg}^{-1}$ s.c.; Metacam®, Barcelona, Spain), enrofloxacin ($7.5 \text{ mg} \cdot \text{kg}^{-1}$ i.p.; Baytril® 2.5%; Barcelona, Spain), atipamezole hydrochloride ($0.5 \text{ mg} \cdot \text{kg}^{-1}$ i.p.; Revertor®, Barcelona, Spain), and 1 ml glucose 5% solution were injected after the surgery.

2.4.2. Acquisition of MDPV self-administration

Self-administration experiments were conducted as described previously (Lujan et al., 2020; Soria et al., 2008). Mice were trained for 2h/day to nose poke to receive a 0.05 or 0.075 mg/kg/infusion of MDPV on 10 consecutive days, under a fixed ratio 1 (FR1) reinforcement schedule. When mice responded at the active hole, the stimulus light lit up for 4 s and an MPDV infusion was delivered automatically. Each infusion was followed by a 15-s time-out period in which a nose poke through the active hole had no consequences. Mice were considered to have acquired stable self-administration behaviour when the following criteria were met in 2 consecutive FR1 sessions: (i) 80% of stability in reinforcements (the number of reinforces on each day deviated by $< 20\%$ from the mean number of reinforces over the 2 consecutive days); (ii) $\geq 65\%$ of responses were received at the active hole; and (iii) a minimum of 5 infusions per session. Mice that met the acquisition criteria were considered high-responders and mice that did not were considered low-responders for this task. Animals received a vehicle or CBD (20 mg/kg, i.p.) injection immediately before each session.

2.4.3. Progressive ratio test

Mice underwent the progressive ratio (PR) test 24 h after the last day of acquisition. The PR test consisted of a single-session test that lasted 2 h. In this session, the requirement to earn an infusion escalated according to the following series: 1-2-3-5- 12-18-27-40-60-90-135-200-300-450-675-1000. The breaking point is the last ratio reached by each animal, which is considered the highest effort the mouse makes to obtain an infusion. Mice received a vehicle or CBD (20 mg/kg, i.p.) injection immediately before the PR session.

2.5. Elevated plus maze (EPM)

The EPM was adapted from Alegre-Zurano et al. (2020b) to evaluate anxiety-like behaviour in mice. The apparatus (Panlab s.l.u., Barcelona, Spain) consisted of a black maze with four arms (16×5 cm) set in the form of a cross from a neutral central square (5×5 cm). Two arms were closed up by vertical walls (closed arms) while the other two perpendicular arms had open edges (open arms). The maze was elevated 30 cm above the floor in dim lighting conditions (30 lux). The percentage of time spent in the open arm was calculated by dividing the time spent in the open arms between the summation of the time spent in the open and closed arms. Mice received the CBD (20 mg/kg, i.p.) or vehicle injection 30 minutes before starting the test and the MDPV (3 or 4 mg/kg) or saline injection 5 minutes before.

2.6. Statistical analysis

Data are presented as mean \pm SEM. For statistical analysis, we used GraphPad Prism 8.0. Software. For MDPV-induced CPP, we used a two-way ANOVA with *session* (test/pretest) and *treatment* (SAL-VEH/SAL-CBD/MDPV-VEH/MDPV-CBD) as factors. For nose pokes activation in the self-administration experiments, we used a three-way ANOVA with repeated measures, with *hole* (active/inactive) and *time* (self-administration day) as within-subjects factors and *CBD treatment* (VEH/CBD) as between-subjects factor. To analyse the number of infusions in the self-administration experiments, we calculated a two-way ANOVA with repeated measures, with *time* (self-administration day) as a within-subjects factor and *CBD treatment* (VEH/CBD) as a between-subjects factor. We used two-way ANOVA for the analysis of the intake, with *CBD treatment* (VEH-CBD) and *group* (high-responders/low-responders) as factors, and progressive ratio, with *CBD treatment* (VEH/CBD) and *hole* (active/inactive) as factors. Unpaired Student's *t*-tests were calculated for areas under the curve and breaking points. Finally, one-way ANOVA was calculated for the analysis of EPM with *treatment* (SAL-VEH/SAL-CBD/MDPV-VEH/MDPV-CBD) as a factor. When F achieved significance and there was no significant variance in homogeneity, Bonferroni's *post hoc* test was run. The percentage of acquisition was analyzed using Fisher's exact test.

3. RESULTS

3.1. CBD treatment partially prevents MDPV-induced CPP

A two-way ANOVA for the time spent in the drug-paired compartment revealed an effect for *session* (Figure 1; $F_{(1,35)} = 23.56$, $p < 0.001$), *treatment* ($F_{(3,35)} = 5.509$, $p < 0.01$) and their *interaction* ($F_{(3,35)} = 3.573$, $p < 0.05$). Bonferroni's *post hoc* analysis showed that only the MDPV-VEH group spent significantly more time in the drug-paired compartment during the test compared to the pretest ($p < 0.001$). However, the *post hoc* analysis also revealed the MDPV-CBD group almost yielded significance ($p = 0.052$), indicating that CBD treatment mildly attenuated MDPV conditioning.




Figure 1. CBD slightly ameliorate MDPV (2 mg/kg)-induced CPP. (A) Time spent in the drug/saline-paired compartment during the pretest and test ($n = 9-10$ /group). Two-way ANOVA, *** $p < 0.001$.

3.2. CBD does not modify MDPV (0.05 mg/kg)-induced self-administration

Administration of CBD (20 mg/kg) during the acquisition of MDPV (0.05 mg/kg) self-administration did not modify drug-seeking or drug-taking behaviours (Figure 2A). Mice were later divided into low-responders (VEH, $n = 9$; CBD, $n = 9$) and high-responders (VEH, $n = 10$; CBD, $n = 9$) based on whether they met the acquisition criteria or not. Similarly, CBD did not affect any of these groups of mice (Figure 2B-C). A two-way ANOVA for total intake revealed that high responders consumed more MDPV than low-responders (Figure 2D; $F_{(1,33)} = 50.11$, $p < 0.001$), but no effects were found for *CBD treatment* or their *interaction*. The percentage of acquisition was not affected by the *CBD treatment* (Figure 2E).

Regarding the progressive ratio test, only high-responder mice underwent the progressive ratio test, since the MDPV-seeking behaviour of low-responders was not enough to meet the requirements of the task. Two-way ANOVA calculated for the nose pokes conducted during the progressive ratio test showed a significant effect for the

factor *hole* (Figure 2F; $F_{(1,17)} = 26.42$, $p < 0.001$), but no effects were found for *CBD treatment* or their *interaction*. Moreover, the breaking point was not affected by *CBD treatment* (Figure 2F).




Figure 2. CBD does not modify MDPV (0.05 mg/kg/infusion) self-administration. (A) Nose pokes and infusions along the self-administration days and their respective areas under the curve (VEH, $n=19$; CBD, $n=18$). (B) Nose pokes and infusions along the self-administration days and their respective areas under the curve for low-responders (VEH, $n=9$; CBD, $n=9$). (C) Nose pokes and infusions along the self-administration days and

their respective areas under the curve for high-responders (VEH, n=10; CBD, n=9). (D) Total MDPV intake. Two-way ANOVA, *** $p < 0.001$. (E) Percentage of acquisition. (F) Active/inactive nose pokes and breaking point during the progressive ratio test. Two-way ANOVA, *** $p < 0.001$.

3.3. CBD increases MDPV (0.075 mg/kg) reinforcing effects only in high-responders

Administration of CBD (20 mg/kg) during the acquisition of MDPV (0.075 mg/kg) self-administration does not modulate drug-seeking or drug-taking behaviours (Figure 3A). However, when data of low-responders (VEH, n=10; CBD, n=11) and high-responders (VEH, n=7; CBD, n=7) were analyzed independently, we found statistical differences. CBD exerted no effect over low-responders behaviour (Figure 3B). However, for high responders (Figure 3C), the three-way ANOVA for the nose pokes curve revealed a significant effect of *time* ($F_{(9,108)} = 4.29$, $p < 0.001$), *CBD treatment* ($F_{(1,12)} = 5.215$, $p < 0.05$), *hole* ($F_{(1,12)} = 29.64$, $p < 0.001$), as well as the *interactions time x hole* ($F_{(9,108)} = 6.336$, $p < 0.001$) and *CBD treatment x hole* ($F_{(1,12)} = 6.137$, $p < 0.05$). Bonferroni's *post hoc* for the *CBD treatment x hole* interaction revealed that CBD-treated group conducted more active nose pokes than the control group ($p < 0.05$), as expressed also by the area under the curve (Figure 3C; $t_{(12)} = 2.67$, $p < 0.05$). In the same line, the ANOVA for infusions revealed a significant effect for *time* ($F_{(9, 108)} = 6.258$, $p < 0.001$) and *CBD treatment* ($F_{(1,12)} = 6.185$, $p < 0.05$), with more infusions for the CBD-treated group. Again, the area under the curve was increased in CBD-treated mice (Figure 3C; $t_{(12)} = 2.776$, $p < 0.05$).

A two-way ANOVA for total intake (Figure 3D) revealed significant effects for *CBD treatment* ($F_{(1,31)} = 39.04$, $p < 0.001$), *group* (high vs low-responders; $F_{(1,31)} = 7.092$, $p < 0.05$) and their *interaction* ($F_{(1,31)} = 7.874$, $p < 0.01$). Bonferroni's *post hoc* showed that CBD-treated high-responder mice consumed more than vehicle-treated high-responders ($p < 0.01$) and more than CBD-treated low-responders ($p < 0.001$). The percentage of acquisition was not affected by the *CBD treatment* (Figure 3E).

Again, only high-responder mice underwent the progressive ratio test. A two-way ANOVA for the nose pokes conducted during the progressive ratio test revealed a tendency for the factor *hole* ($F_{(1,12)} = 4.617$, $p = 0.052$), but no effects for *CBD treatment* or their *interaction*. Moreover, the breaking point was not affected by *CBD treatment*.




Figure 3. CBD increases MDPV (0.075 mg/kg/infusion) self-administration only for high responder mice. (A) Nose pokes and infusions along the self-administration days and their respective areas under the curve (VEH, n=17; CBD, n=18). (B) Nose pokes and infusions along the self-administration days and their respective areas under the curve for low-responders (VEH, n=10; CBD, n=11). (C) Nose pokes and infusions along the self-administration days and their respective areas under the curve for high-responders (VEH, n=7; CBD, n=7). Three-way ANOVA, * $p < 0.05$; Two-way ANOVA, * $p < 0.05$. (D) Total MDPV intake. Bonferroni, ### $p < 0.001$, ** $p < 0.01$ vs vehicle low-

responders. (E) Percentage of acquisition. (F) Active/inactive nose pokes and breaking point during the progressive ratio test. Two-way ANOVA, *** $p < 0.001$.

3.4. Mice modulate their drug-seeking behaviour to maintain MDPV consumption

CBD effects on drug-seeking and taking behaviours for both doses of MDPV (0.05 and 0.075 mg/kg/infusion) were analyzed for all mice (high- and low-responders). A repeated measures three-way ANOVA for the active nose pokes (Figure 4A) revealed a significant effect for *time* ($F_{(9,612)} = 9.969$, $p < 0.001$), *MDPV dose* ($F_{(1,68)} = 4.841$, $p < 0.05$) and their *interaction* ($F_{(9,612)} = 2.595$, $p < 0.01$). No effects for CBD or any interaction with it were found. Bonferroni's *post hoc* for the interaction *MDPV dose* x *time* revealed that mice self-administering MDPV 0.05 mg/kg/infusion conducted more active responses on days 1 ($p < 0.05$), 6 ($p < 0.01$) and 7 ($p < 0.05$) compared to those self-administering MDPV 0.075 mg/kg/infusion. For the infusions curve (Figure 4B), the factors *time* ($F_{(9,612)} = 9.837$, $p < 0.001$), *MDPV dose* ($F_{(1,68)} = 5.285$, $p < 0.05$) and their *interaction* ($F_{(9,612)} = 2.623$, $p < 0.01$) reached significance. Bonferroni's *post hoc* for the interaction *MDPV dose* x *time* revealed that mice self-administering MDPV 0.05 mg/kg/infusion received more infusions on days 1 ($p < 0.05$), 6 ($p < 0.01$), 7 ($p < 0.05$) and 10 ($p < 0.05$) compared to those self-administering MDPV 0.075 mg/kg/infusion. Again, no effects for CBD or any interaction with it were found. The analysis for the total intake (Figure 4C) revealed no significant differences due to the *MDPV dose* or *CBD treatment*, indicating that mice consumed the same amount of MDPV regardless of the experimental conditions.




Figure 4. Mice modulate their drug-seeking behaviour to maintain MDPV consumption. (A) Active nose pokes and (B) infusions along the self-administration. (C) Total intake of MDPV.

3.5. CBD increases the anxiolytic effects of MDPV in the EPM

One-way ANOVA for the percentage of time spent in open arms (Figure 5A) revealed a significant effect of *treatment* ($F_{(2,52)} = 6.304$, $p < 0.001$). Bonferroni's *post hoc* analysis indicated that CBD treatment increased the percentage of time spent in open arms when administered to the MDPV 3 and 4 mg/kg mice compared to the VEH-SAL ($p < 0.05$) and VEH-CBD ($p < 0.01$) groups. Moreover, mice that received both MDPV 4 mg/kg and CBD increased the percentage of time spent in open arms compared to those that only received MDPV 4 mg/kg ($p < 0.05$). In addition, the one-way ANOVA for the number of entries in open arms revealed a significant effect of *treatment* (Figure 5B; $F_{(2,51)} = 5.04$, $p < 0.001$). The *post hoc* analysis indicated that the number of entries in open arms was increased in the CBD-MDPV 3 mg/kg ($p < 0.05$), VEH-MDPV 4 mg/kg ($p < 0.05$) and CBD-MDPV 4 mg/kg ($p < 0.01$) groups compared to the VEH-SAL

group. Moreover, the number of entries in open arms was also increased in the CBD-MDPV 4 mg/kg group compared to the CBD-SAL group. Finally, the one-way ANOVA for total distance revealed a significant effect of *treatment* (Figure 5C; $F_{(5,50)}=4.65$, $p<0.01$). The *post hoc* analysis of MDPV dose indicated that mice treated with MDPV 3 mg/kg and vehicle traversed more distance compared to the VEH-SAL group ($p<0.05$).




Figure 5. CBD exerts anxiolytic effects in the EPM only when co-administered with MDPV. (A) Percentage of time spent in open arms ($n=9-10/\text{group}$). Bonferroni, $*p<0.05$ vs VEH-SAL, # $p<0.05$ vs VEH-MDPV 4 mg/kg. (B) Number of entries in open arms. Bonferroni, $*p<0.05$ vs VEH-SAL, $**p<0.01$ vs VEH-SAL. (C) Total distance travelled. Bonferroni, $*p<0.05$ vs VEH-SAL.

4. DISCUSSION

In the present report, we evaluated the CBD (20 mg/kg) modulation of MDPV motivational effects in mice. The current results provide evidence of the mild mitigation of MDPV-induced CPP due to CBD treatment. On the contrary, CBD administration throughout MDPV self-administration increased drug-seeking and taking behaviours, but only in the high-responders group of mice with an MDPV dose of 0.075 mg/kg/infusion. Additionally, we observed that acute administration of CBD increased the anxiolytic-like effects elicited by MDPV.

Previous research has evidenced that the MDPV-induced CPP at doses similar to that used in this study in both rats (King et al., 2015) and mice (Duart-Castells et al., 2020). Here, we confirmed the expression of CPP induced by MDPV 2 mg/kg, i.p. However, the CBD effects on this paradigm only showed a mild attenuation of MDPV rewarding effects. We previously reported that CBD pretreatment (10 and 20 mg/kg) decreased the

acquisition of cocaine-induced CPP (Luján et al., 2018). Nevertheless, recent studies using a more similar approach (that is, CBD treatment during cocaine-induced CPP conditioning) did not reveal differences due to CBD 10 mg/kg (Chesworth and Karl, 2020) or CBD 30 and 60 mg/kg administration (Ledesma et al., 2021). Similarly, CBD (5 mg/kg) administered during the conditioning phase did not modulate the expression of amphetamine-induced place preference (Parker et al., 2004). Taken together, these data suggest that, except in rare cases, CBD does not affect the rewarding effects of psychostimulants. Moreover, CBD modulation of the CPP paradigm is highly dependent on the psychostimulant used, as supported by previous studies highlighting the behavioural and molecular differences between cocaine and MDPV (Duart-Castells et al., 2020, 2019a, 2019b).

As mentioned above, MDPV serves as a reinforcer in the intravenous self-administration paradigm in rats (Watterson and Olive, 2014). In the present study, MDPV at the doses of 0.05 and 0.075 mg/kg/infusion induced similar levels of drug intake in the self-administration paradigm. Therefore, mice receiving the lower dose of MDPV increased the number of nose pokes and infusions to obtain the same amount of drug as mice receiving the higher dose of the psychostimulant. The percentage of acquisition reached was around 50% of mice under our experimental conditions, which differ from previous studies where up to 80% of rats acquired (Aarde et al., 2015a). These differences might be due to methodological variations (i.e. acquisition criteria, duration of the sessions, days of self-administration, MDPV doses, etc.) or to species-dependent changes in the response to MDPV. In this sense, previous work in our laboratory using other psychostimulants as reinforcers reached variable rates of acquisition depending on the drug, that is, 80-90% for cocaine (Luján et al., 2018) and 57-67% for 3,4-methylenedioxymethamphetamine (MDMA) (Tourinho et al., 2008). However, studies using rats (Gannon et al., 2018, 2017a; Simmons et al., 2018) and rhesus monkeys (Collins et al., 2019) suggest that MDPV functions as a more effective reinforcer than cocaine. Therefore, this evidence suggests a more effective role of MDPV in producing reinforcing effects in the self-administration paradigm in rats compared to mice.

CBD administered during the acquisition of self-administration did not modify MDPV intake at any of the doses tested. However, due to the high variability observed in mice response to MDPV (around 50% reaching acquisition criteria regardless of the dose),

we decided to split the group of animals into high- and low-responders for the analysis, to better elucidate CBD effects over these two groups. Previous studies have already evidenced the existence of low- and high-responder rats regarding the relative reinforcing effects of MDPV (Gannon et al., 2021, 2017a), although they used a different criterion for dividing these populations. Surprisingly, although CBD did not modify the percentage of mice reaching the acquisition criteria regardless of the drug dose, CBD modulation of MDPV self-administration was very different in the two populations for the dose of 0.075 mg/kg/infusion. While low-responders were unaffected by CBD, high-responders increased drug-taking behaviour after CBD treatment. Therefore, low- and high-responders not only differ in their response to MDPV but also in the modulation that CBD exerts over it when a higher dose of MDPV is used as a reinforcer.

Previous research has reported that CBD (20 mg/kg) treatment during self-administration decreases the reinforcing effects of natural rewards, such as sucrose (Bi et al., 2019), and cocaine (Galaj et al., 2019; Luján et al., 2019, 2018). However, the motivation to self-administer methamphetamine in a progressive ratio test was only reduced with a high dose of CBD (80 mg/kg) (Hay et al., 2018). This evidence contrasts with the results obtained in this study, where CBD had no effects over MDPV self-administration (and progressive ratio) or even increased it. Several explanations could be responsible for these differential outcomes. First, CBD, at other doses or different schedules of treatment, could have resulted in different outcomes among the groups. Second, MDPV differs from the psychostimulants above mentioned in its potency and targets within the brain (Baumann et al., 2017; Lopez-Arnau et al., 2019; Simmler et al., 2012) and its behavioural and cognitive effects (Baumann et al., 2013; Duarte-Castells et al., 2019b). Therefore, it might be reasonable to consider that the interactions between CBD and MDPV are different from interactions with other psychostimulants. Third, MDPV can exert aversive effects, notably at high doses, as measured in the conditioned taste aversion test (King et al., 2015, 2014; Merluzzi et al., 2014). In addition, the anxiolytic effects of CBD have been also demonstrated (Campos et al., 2013; Luján et al., 2018). These facts support the hypothesis that CBD could be mitigating the aversive effects of MDPV providing a better “environment” for the operant task in the self-administration paradigm. This hypothesis would be following the fact that CBD only

increased MDPV self-administration in the high-responders and at the higher dose of MDPV.

Finally, we assessed the effects of acute MDPV treatment at doses that are shown to cause aversion in rats (King et al., 2015, 2014; Merluzzi et al., 2014) on anxiety-like behaviour and we co-administered CBD to test the possible interactions. Interestingly, we observed that acute administration of CBD exerted anxiolytic-like effects, but only when co-administered with MDPV. Although MDPV increased the number of entries in open arms, this is probably due to the increase in locomotor activity rather than an anxiolytic effect itself. Otherwise, CBD did not modify the number of entries in open arms or the total distance travelled, indicating that its anxiolytic effect was not due to alterations in the locomotor activity. Moreover, CBD had no effects when administered acutely to the vehicle group, which means that the anxiolytic-like effect was due to an interaction with MDPV. This lack of effect of acute administration of CBD in the EPM is in line with a previous study using the same dose (Guimarães et al., 1990) in rats. However, a different study using mice as experimental subjects found an anxiolytic effect for acute administration of CBD with doses ranging from 0.5 to 50 mg/kg (Onaivi and Green, 1990). To the best of our knowledge, this is the first study examining the effects of MDPV acute administration on anxiety-like behaviour, as well as the CBD modulation. Taking this evidence into account, it is reasonable to propose that such anxiolytic effects arising from the CBD and MDPV synergy could be contributing to the CBD-induced increase in MDPV reinforcement. Therefore, more research is needed to fully understand the interaction between these compounds and to shed some light into the molecular mechanisms responsible for such effect.

On this basis, our results suggest that CBD modulation of MDPV-induced responses in mice is very complex and vary depending on the requirements of the task. First, the results obtained in the CPP suggest mild CBD-induced mitigation of the MDPV rewarding effects. However, the results from the self-administration indicate that CBD might be potentiating the reinforcing effects of MDPV. In the same line, CBD also seems to exert anxiolytic effects in combination with MDPV in the EPM paradigm. Given the large preclinical evidence supporting the protective role of CBD in psychostimulant addictive-like behaviours and the results obtained in this study, more research attempting to decipher the behavioural and molecular interactions between CBD and MDPV is needed.

REFERENCES

- Aarde, S.M., Creehan, K.M., Vandewater, S.A., Dickerson, T.J., Taffe, M.A., 2015a. In vivo potency and efficacy of the novel cathinone α -pyrrolidinopentiophenone and 3,4-methylenedioxypyrovalerone: self-administration and locomotor stimulation in male rats. *Psychopharmacology (Berl)*. 232, 3045–55.
<https://doi.org/10.1007/s00213-015-3944-8>
- Aarde, S.M., Huang, P.K., Creehan, K.M., Dickerson, T.J., Taffe, M.A., 2013. The novel recreational drug 3,4-methylenedioxypyrovalerone (MDPV) is a potent psychomotor stimulant: self-administration and locomotor activity in rats. *Neuropharmacology* 71, 130–40.
<https://doi.org/10.1016/j.neuropharm.2013.04.003>
- Aarde, S.M., Huang, P.K., Dickerson, T.J., Taffe, M.A., 2015b. Binge-like acquisition of 3,4-methylenedioxypyrovalerone (MDPV) self-administration and wheel activity in rats. *Psychopharmacology (Berl)*. 232, 1867–77.
<https://doi.org/10.1007/s00213-014-3819-4>
- Alegre-Zurano, L., Luján, M.Á., Cantacorps, L., Martín-Sánchez, A., García-Baos, A., Valverde, O., 2020a. Cannabidiol effects on cocaine-seeking behaviour and incubation of craving in mice. *bioRxiv* 2020.12.18.423391.
<https://doi.org/10.1101/2020.12.18.423391>
- Alegre-Zurano, L., Martín-Sánchez, A., Valverde, O., 2020b. Behavioural and molecular effects of cannabidiolic acid in mice. *Life Sci*. 259, 118271.
<https://doi.org/10.1016/j.lfs.2020.118271>
- Baumann, M.H., Bukhari, M.O., Lehner, K.R., Anizan, S., Rice, K.C., Concheiro, M., Huestis, M.A., 2017. Neuropharmacology of 3,4-Methylenedioxypyrovalerone (MDPV), Its Metabolites, and Related Analogs HHS Public Access. *Curr Top Behav Neurosci* 32, 93–117. https://doi.org/10.1007/7854_2016_53
- Baumann, M.H., Partilla, J.S., Lehner, K.R., Thorndike, E.B., Hoffman, A.F., Holy, M., Rothman, R.B., Goldberg, S.R., Lupica, C.R., Sitte, H.H., Brandt, S.D., Tella, S.R., Cozzi, N. V, Schindler, C.W., 2013. Powerful Cocaine-Like Actions of 3,4-Methylenedioxypyrovalerone (MDPV), a Principal Constituent of Psychoactive ‘Bath Salts’ Products. *Neuropsychopharmacology* 38, 552–562.

<https://doi.org/10.1038/npp.2012.204>

- Bi, G.-H., Galaj, E., He, Y., Xi, Z.-X., 2019. Cannabidiol inhibits sucrose self-administration by CB1 and CB2 receptor mechanisms in rodents. *Addict. Biol.* e12783. <https://doi.org/10.1111/adb.12783>
- Campos, A.C., Ortega, Z., Palazuelos, J., Fogaça, M. V., Aguiar, D.C., Díaz-Alonso, J., Ortega-Gutiérrez, S., Vázquez-Villa, H., Moreira, F.A., Guzmán, M., Galve-Roperh, I., Guimarães, F.S., 2013. The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: Involvement of the endocannabinoid system. *Int. J. Neuropsychopharmacol.* 16, 1407–1419. <https://doi.org/10.1017/S1461145712001502>
- Chesworth, R., Karl, T., 2020. Cannabidiol (CBD) reduces cocaine-environment memory in mice. *Pharmacol. Biochem. Behav.* 199. <https://doi.org/10.1016/j.pbb.2020.173065>
- Collins, G.T., Sulima, A., Rice, K.C., France, C.P., 2019. Self-administration of the synthetic cathinones 3,4-methylenedioxypyrovalerone (MDPV) and α -pyrrolidinopentiophenone (α -PVP) in rhesus monkeys. *Psychopharmacology (Berl)*. 236, 3677–3685. <https://doi.org/10.1007/s00213-019-05339-4>
- de Mello Schier, A.R., de Oliveira Ribeiro, N.P., Coutinho, D.S., Machado, S., Arias-Carrión, O., Crippa, J.A., Zuardi, A.W., Nardi, A.E., Silva, A.C., 2014. Antidepressant-like and anxiolytic-like effects of cannabidiol: a chemical compound of *Cannabis sativa*. *CNS Neurol. Disord. Drug Targets* 13, 953–60.
- Duart-Castells, L., Carmen Blanco-Gandía, M., Ferrer-Pérez, C., Puster, B., Pubill, D., Miñarro, J., Escubedo, E., Rodríguez-Arias, M., 2020. Cross-reinstatement between 3,4-methylenedioxypyrovalerone (MDPV) and cocaine using conditioned place preference. *Prog. Neuropsychopharmacol. Biol. Psychiatry* 100, 109876. <https://doi.org/10.1016/j.pnpbp.2020.109876>
- Duart-Castells, L., López-Arnau, R., Buenrostro-Jáuregui, M., Muñoz-Villegas, P., Valverde, O., Camarasa, J., Pubill, D., Escubedo, E., 2019a. Neuroadaptive changes and behavioral effects after a sensitization regime of MDPV. *Neuropharmacology* 144, 271–281. <https://doi.org/10.1016/j.neuropharm.2018.10.005>

- Duart-Castells, L., López-Arnau, R., Vizcaíno, S., Camarasa, J., Pubill, D., Escubedo, E., 2019b. 7,8-Dihydroxyflavone blocks the development of behavioral sensitization to MDPV, but not to cocaine: Differential role of the BDNF-TrkB pathway. *Biochem. Pharmacol.* 163, 84–93.
<https://doi.org/10.1016/j.bcp.2019.02.004>
- Elsaid, S., Kloiber, S., Le Foll, B., 2019. Effects of cannabidiol (CBD) in neuropsychiatric disorders: A review of pre-clinical and clinical findings, in: *Progress in Molecular Biology and Translational Science*. Elsevier B.V., pp. 25–75. <https://doi.org/10.1016/bs.pmbts.2019.06.005>
- EMCDDA, 2020. European Drug Report 2020: Trends and Developments.
<https://doi.org/10.2810/123451>
- Fantegrossi, W.E., Gannon, B.M., Zimmerman, S.M., Rice, K.C., 2013. In vivo effects of abused “bath salt” constituent 3,4-methylenedioxypyrovalerone (MDPV) in mice: drug discrimination, thermoregulation, and locomotor activity. *Neuropsychopharmacology* 38, 563–73. <https://doi.org/10.1038/npp.2012.233>
- Galaj, E., Bi, G.-H., Yang, H.-J., Xi, Z.-X., 2019. Cannabidiol attenuates the rewarding effects of cocaine in rats by CB2, 5-TH1A and TRPV1 receptor mechanisms. *Neuropharmacology* 107740.
<https://doi.org/10.1016/J.NEUROPHARM.2019.107740>
- Gannon, B.M., Baumann, M.H., Walther, D., Jimenez-Morigosa, C., Sulima, A., Rice, K.C., Collins, G.T., 2018. The abuse-related effects of pyrrolidine-containing cathinones are related to their potency and selectivity to inhibit the dopamine transporter. *Neuropsychopharmacology*. <https://doi.org/10.1038/s41386-018-0209-3>
- Gannon, B.M., Galindo, K.I., Rice, K.C., Collins, G.T., 2017a. Individual Differences in the Relative Reinforcing Effects of 3,4-Methylenedioxypyrovalerone under Fixed and Progressive Ratio Schedules of Reinforcement in Rats. *J. Pharmacol. Exp. Ther.* *J Pharmacol Exp Ther* 361, 181–189.
<https://doi.org/10.1124/jpet.116.239376>
- Gannon, B.M., Rice, K.C., Murnane, K.S., 2021. MDPV “high-responder” rats also self-administer more oxycodone than their “low-responder” counterparts under a

- fixed ratio schedule of reinforcement. *Psychopharmacology (Berl)*. 1–10.
<https://doi.org/10.1007/s00213-021-05764-4>
- Gannon, B.M., Russell, L.N., Modi, M.S., Rice, K.C., Fantegrossi, W.E., 2017b. Effects of orally self-administered bath salt constituent 3,4-methylenedioxypyrovalerone (MDPV) in mice. *Drug Alcohol Depend.* 179, 408.
<https://doi.org/10.1016/J.DRUGALCDEP.2017.06.031>
- García-Gutiérrez, M.S., Navarrete, F., Gasparyan, A., Austrich-Olivares, A., Sala, F., Manzanares, J., 2020. Cannabidiol: A potential new alternative for the treatment of anxiety, depression, and psychotic disorders. *Biomolecules* 10, 1–34.
<https://doi.org/10.3390/biom10111575>
- Geste, J.R., Pompilus, M., Febo, M., Bruijnzeel, A.W., 2018. Self-administration of the synthetic cathinone MDPV enhances reward function via a nicotinic receptor dependent mechanism. *Neuropharmacology* 137, 286–296.
<https://doi.org/10.1016/j.neuropharm.2018.05.008>
- Guimarães, F.S., Chiaretti, T.M., Graeff, F.G., Zuardi, A.W., 1990. Antianxiety effect of cannabidiol in the elevated plus-maze. *Psychopharmacology (Berl)*. 100, 558–9.
- Hay, G.L., Baracz, S.J., Everett, N.A., Roberts, J., Costa, P.A., Arnold, J.C., McGregor, I.S., Cornish, J.L., 2018. Cannabidiol treatment reduces the motivation to self-administer methamphetamine and methamphetamine-primed relapse in rats. *J. Psychopharmacol.* 32, 1369–1378. <https://doi.org/10.1177/0269881118799954>
- Hicks, C., Huang, P., Ramos, L., Nayak, S.U., Caro, Y., Reitz, A.B., Smith, G.R., Y-W Lee, D., Rawls, S.M., Liu-Chen, L.-Y., 2018. Dopamine D1-Like Receptor Agonist and D2-Like Receptor Antagonist (–)-Stepholidine Reduces Reinstatement of Drug-Seeking Behavior for 3,4-Methylenedioxypyrovalerone (MDPV) in Rats. <https://doi.org/10.1021/acschemneuro.7b00510>
- Izzo, A.A., Borrelli, F., Capasso, R., Di Marzo, V., Mechoulam, R., 2009. Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. *Trends Pharmacol. Sci.* 30, 515–27.
<https://doi.org/10.1016/j.tips.2009.07.006>
- Karch, S., 2014. Cathinone Neurotoxicity (“The “3Ms”). *Curr. Neuropharmacol.* 13, 21–25. <https://doi.org/10.2174/1570159x13666141210225009>

- Karila, L., Lafaye, G., Scocard, A., Cottencin, O., Benyamina, A., 2018. MDPV and α -PVP use in humans: The twisted sisters. *Neuropharmacology*.
<https://doi.org/10.1016/j.neuropharm.2017.10.007>
- King, H.E., Wakeford, A., Taylor, W., Wetzell, B., Rice, K.C., Riley, A.L., 2015. Sex differences in 3,4-methylenedioxypyrovalerone (MDPV)-induced taste avoidance and place preferences. *Pharmacol. Biochem. Behav.* 137, 16–22.
<https://doi.org/10.1016/j.pbb.2015.07.013>
- King, H.E., Wetzell, B., Rice, K.C., Riley, A.L., 2014. 3,4-Methylenedioxypyrovalerone (MDPV)-induced conditioned taste avoidance in the F344/N and LEW rat strains. *Pharmacol. Biochem. Behav.* 126, 163–169.
<https://doi.org/10.1016/j.pbb.2014.09.021>
- Laprairie, R.B., Bagher, A.M., Kelly, M.E.M., Denovan-Wright, E.M., 2015. Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. *Br. J. Pharmacol.* 172, 4790–805. <https://doi.org/10.1111/bph.13250>
- Ledesma, J.C., Manzanedo, C., Aguilar, M.A., 2021. Cannabidiol prevents several of the behavioral alterations related to cocaine addiction in mice. *Prog. Neuro-Psychopharmacology Biol. Psychiatry* 110390.
<https://doi.org/10.1016/j.pnpbp.2021.110390>
- Lopez-Arnau, R., Duart-Castells, L., Aster, B., Camarasa, J., Escubedo, E., Pubill, D., 2019. Effects of MDPV on dopamine transporter regulation in male rats. Comparison with cocaine. *Psychopharmacology (Berl)*. 236, 925–938.
<https://doi.org/10.1007/s00213-018-5052-z>
- Lujan, M.A., Alegre-Zurano, L., Martin-Sanchez, A., Valverde, O., 2020. The effects of cannabidiol on cue- and stress-induced reinstatement of cocaine seeking behavior in mice are reverted by the CB1 receptor antagonist AM4113. *bioRxiv Neurosci.* 2020.01.23.916601. <https://doi.org/10.1101/2020.01.23.916601>
- Luján, M.Á., Cantacorps, L., Valverde, O., 2019. The pharmacological reduction of hippocampal neurogenesis attenuates the protective effects of cannabidiol on cocaine voluntary intake. *Addict. Biol.* e12778. <https://doi.org/10.1111/adb.12778>
- Luján, M.Á., Castro-Zavala, A., Alegre-Zurano, L., Valverde, O., 2018. Repeated Cannabidiol treatment reduces cocaine intake and modulates neural proliferation

- and CB1R expression in the mouse hippocampus. *Neuropharmacology* 143, 163–175. <https://doi.org/10.1016/j.neuropharm.2018.09.043>
- Martínez-Pinilla, E., Varani, K., Reyes-Resina, I., Angelats, E., Vincenzi, F., Ferreiro-Vera, C., Oyarzabal, J., Canela, E.I., Lanciego, J.L., Nadal, X., Navarro, G., Borea, P.A., Franco, R., 2017. Binding and signaling studies disclose a potential allosteric site for cannabidiol in cannabinoid CB2 receptors. *Front. Pharmacol.* 8, 744. <https://doi.org/10.3389/fphar.2017.00744>
- Merluzzi, A.P., Hurwitz, Z.E., Briscione, M.A., Cobuzzi, J.L., Wetzell, B., Rice, K.C., Riley, A.L., 2014. Age-dependent MDPV-induced taste aversions and thermoregulation in adolescent and adult rats. *Dev. Psychobiol.* 56, 943–954. <https://doi.org/10.1002/dev.21171>
- Onaivi, S., Green, M.R., 1990. Pharmacological Characterization of Cannabinoids in the Elevated Plus Maze.
- Parker, L.A., Burton, P., Sorge, R.E., Yakiwchuk, C., Mechoulam, R., 2004. Effect of low doses of Δ^9 -tetrahydrocannabinol and cannabidiol on the extinction of cocaine-induced and amphetamine-induced conditioned place preference learning in rats. *Psychopharmacology (Berl)*. 175, 360–366. <https://doi.org/10.1007/s00213-004-1825-7>
- Risca, H.I., Zuarth-Gonzalez, J.D., Baker, L.E., 2020. Conditioned place preference following concurrent treatment with 3, 4-methylenedioxypyrovalerone (MDPV) and methamphetamine in male and female Sprague-Dawley rats. <https://doi.org/10.1016/j.pbb.2020.173032>
- Ross, E.A., Reisfield, G.M., Watson, M.C., Chronister, C.W., Goldberger, B.A., 2012. Psychoactive “bath salts” intoxication with methylenedioxypyrovalerone. *Am. J. Med.* <https://doi.org/10.1016/j.amjmed.2012.02.019>
- Schindler, C.W., Thorndike, E.B., Goldberg, S.R., Lehner, K.R., Cozzi, N. V., Brandt, S.D., Baumann, M.H., 2016. Reinforcing and neurochemical effects of the “bath salts” constituents 3,4-methylenedioxypyrovalerone (MDPV) and 3,4-methylenedioxy-N-methylcathinone (methyline) in male rats. *Psychopharmacology*. 233, 1981. <https://doi.org/10.1007/S00213-015-4057-0>
- Sewalia, K., Watterson, L.R., Hryciw, A., Belloc, A., Ortiz, J.B., 2018. Neurocognitive

- dysfunction following repeated binge-like self-administration of the synthetic cathinone 3,4-methylenedioxypyrovalerone (MDPV). *Neuropharmacology* 134, 36–45. <https://doi.org/10.1016/J.NEUROPHARM.2017.11.034>
- Simmler, L.D., Buser, T.A., Donzelli, M., Schramm, Y., Dieu, L.-H., Huwyler, J., Chaboz, S., Hoener, M.C., Liechti, M E, Liechti, Matthias E, 2012. Pharmacological characterization of designer cathinones in vitro. <https://doi.org/10.1111/j.1476-5381.2012.02145.x>
- Simmons, S.J., Gregg, R.A., Tran, F.H., Mo, L., Von Weltin, E., Barker, D.J., Gentile, T.A., Watterson, L.R., Rawls, S.M., Muschamp, J.W., 2018. Comparing rewarding and reinforcing properties between “bath salt” 3,4-methylenedioxypyrovalerone (MDPV) and cocaine using ultrasonic vocalizations in rats HHS Public Access. *Addict Biol* 23, 102–110. <https://doi.org/10.1111/adb.12479>
- Simmons, S.J., Martorana, R., Philogene-Khalid, H., Tran, F.H., Gentile, T.A., Xu, X., Su, S., Rawls, S.M., Muschamp, J.W., 2017. Role of hypocretin/orexin receptor blockade on drug-taking and ultrasonic vocalizations (USVs) associated with low-effort self-administration of cathinone-derived 3,4-methylenedioxypyrovalerone (MDPV) in rats. *Psychopharmacology (Berl)*. 234, 3207–3215. <https://doi.org/10.1007/s00213-017-4709-3>
- Soria, G., Barbano, M.F., Maldonado, R., Valverde, O., Soria, G., Barbano, M.F., Maldonado, R., Valverde, O., 2008. A reliable method to study cue-, priming-, and stress-induced reinstatement of cocaine self-administration in mice. *Psychopharmacology (Berl)*. 199, 593–603. <https://doi.org/10.1007/s00213-008-1184-x>
- Soria, G., Mendizábal, V., Touriño, C., Robledo, P., Ledent, C., Parmentier, M., Maldonado, R., Valverde, O., 2005. Lack of CB1 Cannabinoid Receptor Impairs Cocaine Self-Administration. *Neuropsychopharmacology* 30, 1670–1680. <https://doi.org/10.1038/sj.npp.1300707>
- Touriño, C., Ledent, C., Maldonado, R., Valverde, O., 2008. CB1Cannabinoid Receptor Modulates 3,4-Methylenedioxymethamphetamine Acute Responses and Reinforcement. *Biol. Psychiatry* 63, 1030–1038. <https://doi.org/10.1016/j.biopsych.2007.09.003>

United Nations publication, 2020. World Drug Report, World Drug Report.

Watterson, L.R., Kufahl, P.R., Nemirovsky, N.E., Sewalia, K., Grabenauer, M., Thomas, B.F., Marusich, J.A., Wegner, S., Olive, M.F., 2014. Potent rewarding and reinforcing effects of the synthetic cathinone 3,4-methylenedioxypyrovalerone (MDPV). *Addict. Biol.* 19, 165–174. <https://doi.org/10.1111/j.1369-1600.2012.00474.x>

Watterson, L.R., Olive, M.F., 2014. Synthetic cathinones and their rewarding and reinforcing effects in rodents. *The Rise of Synthetic Cathinone Use and Abuse. Advis. Neurosci.* <https://doi.org/10.1155/2014/209875>